SLC22A8 and Decreased liver function: Combining experimental data, it may be stated that decreased OAT1 and OAT3 expression in the patients with liver dysfunction can lead to reduced furosemide transport via OAT1 and OAT3 to its site of action, and thus decreased natriuteric effects.